INVESTABOT
Equity Research
XNAS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Regeneron Pharmaceuticals (REGN) had 1 Form 144 pre-sale notice filed on 2026-09-03. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At…
Regeneron Pharmaceuticals (REGN) had 2 Form 144 pre-sale notices filed on 2026-09-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At…
Regeneron Pharmaceuticals (REGN) had 2 Form 144 pre-sale notices filed on 2026-08-10. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At…
Regeneron Pharmaceuticals (REGN) had 1 Form 144 pre-sale notice filed on 2026-07-02. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At…
TL;DR: Regeneron posted Q1 2026 revenue of $3.6 billion, up 19% from $3.03 billion a year ago, driven by explosive growth across its drug portfolio.
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 3 unique sellers · 8 accumulating - 6 trimming - 0 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 3, 2026 | McCourt Marion | EVP Commercial | SELL | -1,131 | $857 | ~$1.0M |
| September 2, 2026 | Guarini Kathryn | — | OPTION_EXERCISE | 400 | $719 | ~$0.3M |
| September 2, 2026 | Guarini Kathryn | — | SELL | -400 | $850 | ~$0.3M |
| September 2, 2026 | Guarini Kathryn | — | OPTION_EXERCISE | -400 | — | — |
| September 2, 2026 | McCourt Marion | EVP Commercial | SELL | -1,215 | $850 | ~$1.0M |
| August 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | OPTION_EXERCISE | 12,282 | $382 | ~$4.7M |
| August 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | TAX_WITHHOLD | -9,019 | $830 | ~$7.5M |
| August 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | OPTION_EXERCISE | -12,282 | — | — |
| August 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | OPTION_EXERCISE | 6,283 | $382 | ~$2.4M |
| August 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | TAX_WITHHOLD | -4,599 | $813 | ~$3.7M |
| August 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | OPTION_EXERCISE | -6,283 | — | — |
| August 10, 2026 | Guarini Kathryn | — | OPTION_EXERCISE | 400 | $719 | ~$0.3M |
| August 10, 2026 | Guarini Kathryn | — | SELL | -400 | $800 | ~$0.3M |
| August 10, 2026 | Guarini Kathryn | — | OPTION_EXERCISE | -400 | — | — |
| August 10, 2026 | Zoghbi Huda Y | — | OPTION_EXERCISE | 800 | $377 | ~$0.3M |
| August 10, 2026 | Zoghbi Huda Y | — | SELL | -800 | $800 | ~$0.6M |
| August 10, 2026 | Zoghbi Huda Y | — | OPTION_EXERCISE | -800 | — | — |
| July 2, 2026 | Ryan Arthur F | — | SELL | -200 | $650 | ~$0.1M |
| May 1, 2026 | Ryan Arthur F | — | SELL | -5 | $702 | ~$4K |
| May 1, 2026 | Ryan Arthur F | — | SELL | -15 | $702 | ~$11K |
| Date | Filer | Relationship | Est. shares | Filing |
|---|---|---|---|---|
| September 3, 2026 | McCourt Marion | — | 1,131 | SEC |
| September 2, 2026 | McCourt Marion | — | 1,215 | SEC |
| September 2, 2026 | Guarini Kathryn | — | 400 | SEC |
| August 10, 2026 | Zoghbi Huda Y | — | 800 | SEC |
| August 10, 2026 | Guarini Kathryn | — | 400 | SEC |
| July 2, 2026 | J.P. Morgan Securities LLC as agent and attorney-in-fact for Arthur F. Ryan | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 8,446,366 | ~$8.9B | — | August 13, 2024 |
| Vanguard Group | 9,075,153 | ~$7.0B | — | January 29, 2026 |
| BlackRock | 8,947,735 | ~$6.9B | 2.4% | May 13, 2026 |
| BlackRock | 8,741,270 | ~$6.7B | — | February 12, 2026 |
| BlackRock | 9,113,506 | ~$5.7B | 1.9% | August 7, 2026 |
| State Street | 4,664,478 | ~$3.6B | 0.1% | May 15, 2026 |
| State Street | 4,660,808 | ~$3.6B | — | February 13, 2026 |
| JP Morgan Chase | 4,336,806 | ~$3.2B | 8.4% | May 13, 2026 |
| JP Morgan Chase | 4,002,160 | ~$3.1B | — | February 11, 2026 |
| State Street | 4,834,688 | ~$3.0B | 3.6% | August 7, 2026 |
| JP Morgan Chase | 3,774,199 | ~$2.4B | -13.0% | August 12, 2026 |
| Fidelity (FMR) | 2,319,566 | ~$1.8B | — | February 17, 2026 |
| Fidelity (FMR) | 1,518,192 | ~$1.2B | -34.5% | May 15, 2026 |
| Goldman Sachs | 1,504,658 | ~$1.2B | 13.3% | May 15, 2026 |
| Morgan Stanley | 1,389,323 | ~$1.1B | — | May 27, 2026 |
| Goldman Sachs | 1,327,627 | ~$1.0B | — | March 25, 2026 |
| Morgan Stanley | 1,319,329 | ~$1.0B | -5.0% | May 15, 2026 |
| AQR Capital | 1,231,008 | ~$946.0M | 23.6% | May 15, 2026 |
| Morgan Stanley | 1,397,712 | ~$871.5M | 5.9% | August 13, 2026 |
| Goldman Sachs | 1,334,291 | ~$832.0M | -11.3% | August 14, 2026 |